Robinson Chandler D.'s most recent trade in Monopar Therapeutics Inc was a trade of 9,801 shares done . Disclosure was reported to the exchange on Sept. 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2026 | 9,801 | 109,068 (1%) | 0% | - | - | |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.67 per share. | 30 Sep 2026 | 4,344 | 104,724 (0%) | 0% | 79.7 | 346,086 | - |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 24 Sep 2026 | 15,000 | 128,323 (1%) | 0% | 14 | 210,000 | - |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 24 Sep 2026 | 14,056 | 113,323 (1%) | 0% | 30 | 421,680 | - |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.15 per share. | 24 Sep 2026 | 10,450 | 117,873 (1%) | 0% | 87.2 | 910,718 | - |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.96 per share. | 24 Sep 2026 | 9,638 | 108,235 (1%) | 0% | 88.0 | 847,758 | - |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.97 per share. | 24 Sep 2026 | 8,368 | 99,867 (0%) | 0% | 89.0 | 744,501 | - |
| Monopar Therapeutics Inc | Dr. Chandler D. Robinson, M. Sc.,M.B.A.,M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 89.79 per share. | 24 Sep 2026 | 600 | 99,267 (0%) | 0% | 89.8 | 53,874 | - |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 12,873 | 93,403 | - | - | Restricted Stock Unit | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 12,873 | 103,351 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.59 per share. | 30 Jun 2026 | 4,084 | 99,267 (0%) | 0% | 92.6 | 378,138 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 6,732 | 106,276 | - | - | Restricted Stock Unit | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 6,732 | 92,450 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.79 per share. | 31 Mar 2026 | 1,972 | 90,478 (0%) | 0% | 54.8 | 108,046 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 8,724 | 88,276 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 8,724 | 113,008 | - | - | Restricted Stock Unit | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.30 per share. | 31 Dec 2025 | 2,558 | 85,718 (0%) | 0% | 65.3 | 167,037 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2025 | 49,133 | 121,732 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2025 | 16,753 | 16,753 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 8,726 | 72,599 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 8,726 | 82,198 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.67 per share. | 30 Sep 2025 | 2,646 | 79,552 (0%) | 0% | 81.7 | 216,099 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | 14 Jul 2025 | 16,800 | 0 | - | - | Stock Options | ||
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Jul 2025 | 16,800 | 73,472 (0%) | 0% | 40.0 | 672,020 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | 14 Jul 2025 | 16,800 | 90,272 (0%) | 0% | 0.0 | 84 | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 13,344 | 79,337 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 13,344 | 81,325 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.78 per share. | 30 Jun 2025 | 5,865 | 73,472 (0%) | 0% | 35.8 | 209,850 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 4,106 | 67,197 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 4,106 | 94,669 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.41 per share. | 31 Mar 2025 | 1,204 | 65,993 (0%) | 0% | 36.4 | 43,838 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 85,759 | 85,759 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 79,899 | 104,777 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 6,002 | 64,850 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 6,002 | 98,775 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.70 per share. | 04 Mar 2025 | 1,759 | 63,091 (0%) | 0% | 31.7 | 55,760 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 28 Jan 2025 | 62,815 | 62,815 (0%) | 0% | 0 | Common Stock | |
| Monopar Therapeutics Inc | D. Robinson Chandler | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 4,895 | 24,879 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler Robinson D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 4,895 | 61,057 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | D. Robinson Chandler | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.00 per share. | 31 Dec 2024 | 2,209 | 58,848 (0%) | 0% | 22 | 48,598 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 4,895 | 58,080 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2024 | 4,895 | 29,774 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 30 Sep 2024 | 1,918 | 56,162 (0%) | 0% | 6.7 | 12,927 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 24,476 | 274,606 (2%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 24,476 | 173,335 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.73 per share. | 30 Jun 2024 | 8,684 | 265,922 (2%) | 0% | 0.7 | 6,348 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | 28 May 2024 | 84,000 | 0 | - | - | Stock Options | ||
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | 28 May 2024 | 84,000 | 250,130 (2%) | 0% | 0.0 | 84 | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 24,474 | 197,811 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 24,474 | 173,302 (1%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.68 per share. | 31 Mar 2024 | 7,172 | 166,130 (1%) | 0% | 0.7 | 4,884 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 24,474 | 229,009 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Robinson D. Chandler | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 24,474 | 152,900 (1%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler Robinson D. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 31 Dec 2023 | 8,469 | 144,431 (1%) | 0% | 0.3 | 2,881 | Common Stock |
| Monopar Therapeutics Inc | D. Chandler Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 6,724 | 151,155 (1%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Robinson D. Chandler | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 6,724 | 222,285 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Robinson Chandler D. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.34 per share. | 31 Dec 2023 | 2,327 | 148,828 (1%) | 0% | 0.3 | 792 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 35,039 | 121,393 (1%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 35,039 | 277,957 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 30 Jun 2023 | 10,269 | 111,124 (1%) | 0% | 0.9 | 8,780 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 13,911 | 90,640 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 13,911 | 312,996 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 31 Mar 2023 | 4,286 | 86,354 (0%) | 0% | 1.4 | 5,958 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 221,839 | 221,839 | - | - | Stock Options | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 169,012 | 326,907 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 13,912 | 151,171 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 13,912 | 77,147 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 6,723 | 6,724 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 6,723 | 79,056 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 31 Dec 2022 | 4,814 | 72,333 (0%) | 0% | 2.4 | 11,409 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.37 per share. | 31 Dec 2022 | 2,327 | 76,729 (0%) | 0% | 2.4 | 5,515 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 13,911 | 178,530 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 13,911 | 67,312 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.52 per share. | 30 Sep 2022 | 4,077 | 63,235 (0%) | 0% | 1.5 | 6,197 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 23,882 | 192,441 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 23,882 | 60,400 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.30 per share. | 30 Jun 2022 | 6,999 | 53,401 (0%) | 0% | 2.3 | 16,091 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 3,941 | 216,323 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 3,941 | 37,673 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.55 per share. | 31 Mar 2022 | 1,155 | 36,518 (0%) | 0% | 2.5 | 2,945 | Common Stock |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,724 | 36,059 (0%) | 0% | - | Common Stock | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,724 | 13,447 | - | - | Restricted Stock Units | |
| Monopar Therapeutics Inc | Chandler D. Robinson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.21 per share. | 01 Jan 2022 | 2,327 | 33,732 (0%) | 0% | 3.2 | 7,470 | Common Stock |